Danaher Corporation (DHR)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$194.18+0.29%
Close 2026-07-07 · 1-day change
Reading DHR? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DHR free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading DHR? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DHR free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 4% over the past year.
View GrowthManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskDanaher's growth trajectory relies on its ability to expand core revenue by 3% to 6%, which is essential to justify its current valuation. Revenue grew 3.5% year over year in the latest quarter, and the company beat earnings expectations by 6.2%. It trades at 24.3× P/E versus a peer median of 35.4×, indicating that the price reflects less growth than forecasted. A specific risk is the potential for a guidance cut, with a 15% probability of missing expectations in the next quarter. Peer multiples imply a price roughly in line with where it trades. This read is provisional.
Trailing returns as of 2026-07-07. DHR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 26 analysts currently covering DHR (as of Jul 2026).
Based on 8 Wall Street analysts offering 12-month price targets for DHR in the last 4 months.
A consensus fair price across 12 valuation methods, at three horizons. Current price $194.18. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Threatens: Grow core revenue 3% to 6%
Recovery fell short, impacting growth expectations.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $194.18
The last 12 months of price, then the range of analyst 12-month targets from today’s $194.18.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase EPS guidance
Earnings beat estimates, supporting EPS guidance.
Threatens: Grow core revenue 3% to 6%
Larger drop than market indicates potential growth issues.
Advances: Grow core revenue 3% to 6%
Aldevron buyout aids growth in genomic medicine.